Alto Neuroscience (NYSE:ANRO) Shares Up 1.8%

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) traded up 1.8% during trading on Tuesday . The stock traded as high as $14.30 and last traded at $13.88. 85,381 shares were traded during trading, a decline of 65% from the average session volume of 241,218 shares. The stock had previously closed at $13.64.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, February 27th. They set a “buy” rating and a $33.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price target on shares of Alto Neuroscience in a research report on Monday, March 25th. TD Cowen assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, February 27th. They set an “outperform” rating for the company. Robert W. Baird assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, February 27th. They set an “outperform” rating and a $32.00 price target for the company. Finally, William Blair assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, February 27th. They issued an “outperform” rating for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $32.33.

Alto Neuroscience Stock Performance

The company has a 50-day simple moving average of $14.69.

Insider Transactions at Alto Neuroscience

In other news, major shareholder Wave Global Lp Alpha purchased 600,000 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was acquired at an average cost of $16.00 per share, with a total value of $9,600,000.00. Following the acquisition, the insider now owns 3,707,757 shares in the company, valued at $59,324,112. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder Wave Global Lp Alpha purchased 600,000 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was acquired at an average cost of $16.00 per share, with a total value of $9,600,000.00. Following the acquisition, the insider now owns 3,707,757 shares in the company, valued at $59,324,112. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Nicholas Conrad Smith purchased 6,150 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were purchased at an average cost of $16.36 per share, with a total value of $100,614.00. Following the completion of the acquisition, the chief financial officer now owns 26,866 shares in the company, valued at approximately $439,527.76. The disclosure for this purchase can be found here.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.